Print Page     Close Window     

SEC Filings

20-F
AC IMMUNE SA filed this Form 20-F on 03/21/2019
Entire Document
 

 

For the years ended December 31, 2018, 2017 and 2016, the Company has recognized 0.3 million, CHF 0.1 million and nil, respectively. The Company has recorded all revenues from this grant through December 31, 2018.

 

Following the successful completion of this grant extension in 2018, we received an additional grant in November 2018 to conduct a first-in-human (FIH) study in H1 2019. No revenues were recorded as of December 31, 2018.

 

12.Expenses by Category

 

Research and Development

 

 

For the Years Ended

December 31,

in CHF thousands 2018   2017   2016
Operating expenses 32,921   23,822   18,767
Payroll expenses 10,662   8,552   6,450
Share-based compensation 694   289   557
Total research and development expenses 44,277   32,663   25,774

 

General and Administrative

 

 

For the Years Ended

December 31,

in CHF thousands 2018   2017   2016
Operating expenses 4,903   3,857   3,168
Payroll expenses 5,740   4,984   3,969
Share-based compensation 1,824   1,290   759
Total general and administrative expenses 12,467   10,131   7,896

 

Financial Result, net

 

 

For the Years Ended

December 31,

in CHF thousands 2018   2017   2016
Interest income/ (expense) (269)   184   36
Foreign currency remeasurement gain/(loss), net (1,194)   (4,049)   3,443
Other finance income/(expense) 62   (7)   (119)
Finance result, net (1,401)   (3,872)   3,360

 

13.Related-party transactions

 

Key management, including the Board of Directors (seven individuals excluding the CEO) and the Executive Management (four individuals including the CEO), compensation was:

 

 

For the Years Ended

December 31,

in CHF thousands 2018   2017   2016
Short-term employee benefits 2,681   2,463   2,251
Post-employment benefits 160   166   154
Share-based compensation 1,683   1,267   832
Total 4,524   3,896   3,237

 

 F-27


© AC Immune 2015